#USA #New York #Gross Law Firm #Ultragenyx #RARE

Ultragenyx Pharmaceutical Inc. Shareholder Alert: Join the Class Action Lawsuit

The Gross Law Firm has issued a crucial alert to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), urging them to take action following significant downturns in stock prices. This notice pertains to investors who acquired shares during the class period, which spans from August 3, 2023, to December 26, 2025.

Background of the Class Action

The lawsuit arises from a series of misleading statements made by the company's management regarding the potential and effectiveness of the drug setrusumab. According to the complaints, Ultragenyx provided investors with overly optimistic projections about the drug's efficacy while concealing critical information regarding its actual performance in clinical trials. Specifically, despite claims of increased bone density, the data did not support a reduction in fracture rates, which is a key metric for success in the ongoing studies, known as the Phase III Orbit and Cosmic studies.

On December 29, 2025, the company revealed that these studies had failed to meet primary endpoints, resulting in a drastic stock price decline from $34.19 to $19.72 — a staggering drop of approximately 42.32% in just one day. This illuminating development caught the attention of many shareholders who were previously led to believe in the positive outcomes suggested by the company.

Who Can Join?

The law firm encourages frustrated shareholders to contact them for the possibility of being appointed lead plaintiffs in the ongoing lawsuit. Such a role is not mandatory to recover any losses incurred. Investors who purchased shares within the specified timeframe are welcome to register and will be included in any subsequent updates regarding the legal proceedings.

Upcoming Deadlines and Next Steps

Shareholders must not hesitate, as the deadline to register for participation in this class action lawsuit is set for April 6, 2026. Interested parties can submit their information through the designated registration link provided by the Gross Law Firm. Upon registering, investors will gain access to portfolio monitoring tools that will keep them updated on the lawsuit's status and developments.

Why Choose the Gross Law Firm?

With a strong reputation as a nationally recognized class action firm, the Gross Law Firm is committed to protecting investors against malpractice and ensuring companies adhere to ethical business practices. Their mission is to recover losses for investors misled by deceptive practices and false statements from companies. The firm emphasizes that participation in the lawsuit carries no financial obligation for shareholders.

In light of the recent tumultuous shifts in Ultragenyx’s stock performance, those affected by the company's practices are urged to act swiftly and ensure their voice is heard in this significant legal undertaking.

For further inquiries or to initiate the registration process, shareholders can contact the Gross Law Firm directly via phone or email, or access the registration link provided.

• ---

Contact Information
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Stay informed and advocate for your rights as a shareholder in Ultragenyx Pharmaceutical Inc. in light of this ongoing class action lawsuit.